Lindbrook Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Lindbrook Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$3.39K	Sell	276 -268	-49%	-$3.78K	﹤0.01%	2106
2024 Q4	$7.19K	Sell	544 -172	-24%	-$2.94K	﹤0.01%	1817
2024 Q3	$13.8K	Sell	716 -63	-8%	-$1.3K	﹤0.01%	1508
2024 Q2	$16K	Sell	779 -23	-3%	-$481	﹤0.01%	1375
2024 Q1	$19.1K	Buy	802 +46	+6%	+$1.03K	﹤0.01%	1239
2023 Q4	$16.3K	Buy	756 +661	+696%	+$10.2K	﹤0.01%	1306
2023 Q3	$1.38K	Buy	95 +20	+27%	+$378	﹤0.01%	2256
2023 Q2	$1.57K	Sell	75 -124	-62%	-$2.58K	﹤0.01%	2242
2023 Q1	$4.2K	Buy	199 +104	+109%	+$2.59K	﹤0.01%	1923
2022 Q4	$2.42K	Sell	95 -164	-63%	-$3.83K	﹤0.01%	2162
2022 Q3	$6K	Buy	259 +224	+640%	+$5.03K	﹤0.01%	1594
2022 Q2	$1K	Buy	+35	New	+$583	﹤0.01%	2361

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's SNDX Position: Q1 2025 in Review

Lindbrook Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 49% in Q1 2025, selling an estimated $3.78K and leaving 276 shares worth $3.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

Lindbrook Capital first reported a position in SNDX in Q2 2022 and has held it in 12 quarters since. The position peaked at $19.1K in Q1 2024. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

Lindbrook Capital held 276 shares of Syndax Pharmaceuticals worth $3.39K as of Q1 2025.
Lindbrook Capital sold 268 Syndax Pharmaceuticals shares in Q1 2025, an estimated $3.78K.
Syndax Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2106 holding.
Lindbrook Capital first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
Lindbrook Capital's Syndax Pharmaceuticals position peaked at $19.1K in Q1 2024.
218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.